# Lecture 13: Lysosomes and Autophagy
## Cell Biology
---
## Learning Objectives
By the end of this lecture, students will be able to:
1. Describe the structure, composition, and biogenesis of lysosomes
2. Explain the mannose-6-phosphate pathway for lysosomal enzyme targeting
3. Describe the major forms of autophagy and their molecular mechanisms
4. Explain the role of mTOR and AMPK in regulating autophagy
5. Discuss lysosomal storage diseases and the role of lysosomes in disease
---
## Lecture Content
### I. Lysosome Structure and Composition
Lysosomes are membrane-bound organelles that function as the cell's digestive system, breaking down macromolecules delivered via endocytosis, phagocytosis, and autophagy. Their interior is maintained at an acidic pH of approximately 4.5 to 5.0 by the V-type H+-ATPase, a proton pump in the lysosomal membrane. The single limiting membrane is enriched in **LAMP proteins** (LAMP-1 and LAMP-2), which are heavily glycosylated to protect the membrane from degradation by the enzymes within, along with lysosomal integral membrane proteins (LIMPs) and V-type H+-ATPase subunits.
Lysosomes contain approximately 60 different **lysosomal hydrolases**, all of which are acid hydrolases with optimal activity at acidic pH. These include proteases (cathepsins B, D, L, and K), lipases (acid lipase, sphingomyelinase, ceramidase), glycosidases (beta-glucosidase, alpha-galactosidase, hexosaminidase), nucleases (DNase II, RNase), phosphatases (acid phosphatase), and sulfatases (arylsulfatase). All lysosomal hydrolases are synthesized in the ER, modified in the Golgi, and targeted to lysosomes via the mannose-6-phosphate pathway. Lysosomes receive material for degradation from three sources: endocytosis (forming endolysosomes), phagocytosis (forming phagolysosomes), and autophagy (forming autolysosomes).
### II. Lysosomal Enzyme Targeting — The M6P Pathway
The **mannose-6-phosphate (M6P) tagging** system ensures that lysosomal enzymes are specifically directed to lysosomes rather than being secreted. In the cis-Golgi, the enzyme **GlcNAc phosphotransferase** recognizes lysosomal enzymes through a signal patch -- a three-dimensional conformation on the folded protein rather than a linear amino acid sequence -- and transfers GlcNAc-phosphate to mannose residues on N-linked glycans. The **uncovering enzyme** then removes the GlcNAc, exposing the M6P tag.
Two types of **M6P receptors (MPRs)** -- the 46 kDa cation-dependent MPR and the 300 kDa cation-independent MPR -- in the TGN bind M6P-tagged enzymes. Clathrin/AP-1-coated vesicles bud from the TGN carrying the receptor-enzyme complexes and deliver them to late endosomes. The acidic pH of the late endosome causes the enzymes to dissociate from the receptors. The M6P receptors are then recycled to the TGN via the retromer complex, while the released enzymes are activated by proteolytic processing in the acidic environment.
**I-cell disease (Mucolipidosis type II)** dramatically illustrates the importance of this pathway. A defect in GlcNAc phosphotransferase means lysosomal enzymes are not tagged with M6P and are secreted from the cell instead of being delivered to lysosomes. As a result, lysosomes accumulate undigested material, forming visible inclusion bodies. The disease causes severe developmental delay, skeletal abnormalities, and is typically fatal in early childhood.
### III. Lysosomal Storage Diseases
Approximately 50 genetic disorders result from deficiency of specific lysosomal enzymes or transporters, collectively known as lysosomal storage diseases (LSDs). In each case, the accumulation of undigested substrates in lysosomes leads to progressive cell dysfunction and organ damage. Most are autosomal recessive, progressive, and present in infancy or childhood.
**Tay-Sachs disease** results from deficiency of hexosaminidase A, causing GM2 ganglioside accumulation in neurons. It produces devastating neurodegeneration, a characteristic cherry-red spot on the retina, and death by age 3 to 5. It is more prevalent in the Ashkenazi Jewish population. **Gaucher disease**, the most common LSD, is caused by deficiency of glucocerebrosidase and features hepatosplenomegaly, bone disease, and anemia. The non-neuropathic type 1 is treatable with enzyme replacement therapy. **Niemann-Pick disease** encompasses types A and B (sphingomyelinase deficiency) and type C (a cholesterol transport defect involving NPC1/NPC2). **Fabry disease**, which is X-linked, results from alpha-galactosidase A deficiency and leads to renal failure, cardiomyopathy, and neuropathic pain. **Pompe disease**, caused by acid alpha-glucosidase deficiency, leads to glycogen accumulation in lysosomes and was the first LSD treated with enzyme replacement therapy (alglucosidase alfa). **Hurler and Hunter syndromes** are mucopolysaccharidoses caused by defective glycosaminoglycan degradation. **Krabbe disease** results from deficient galactosylceramidase.
Treatment strategies for LSDs include **enzyme replacement therapy** (recombinant enzyme with M6P tag delivered intravenously), **substrate reduction therapy** (inhibiting substrate synthesis, as with miglustat for Gaucher disease), **pharmacological chaperones** (small molecules that stabilize mutant enzymes), **gene therapy** (delivering a functional gene copy, with clinical trials ongoing), and **hematopoietic stem cell transplant** for certain neurological LSDs.
Lysosomal storage diseases overview. Panel A: Normal lysosome with functional enzymes breaking down substrates (gangliosides, sphingolipids, glycosaminoglycans, glycogen) into products that are exported. Panel B: Diseased lysosome with a missing/defective enzyme (marked with X), showing accumulation of undigested substrate causing lysosomal swelling. Panel C: Table listing five major lysosomal storage diseases — Tay-Sachs, Gaucher, Niemann-Pick, Fabry, and Pompe — with the deficient enzyme, accumulating substrate, and key clinical features for each.
### IV. Autophagy — Overview and Types
Autophagy ("self-eating") is the process by which cells degrade their own components via lysosomes. It is essential for cellular homeostasis, quality control, and survival during nutrient stress. Yoshinori Ohsumi received the 2016 Nobel Prize in Physiology or Medicine for elucidating the mechanisms of autophagy in yeast.
Three main types of autophagy are recognized. **Macroautophagy** (commonly referred to simply as "autophagy") involves the formation of a double-membrane vesicle called an autophagosome that engulfs cytoplasmic material. The autophagosome then fuses with a lysosome to form an autolysosome, where the contents are degraded. Macroautophagy can be non-selective (bulk degradation of cytoplasm) or selective (targeting specific cargo). **Microautophagy** involves direct invagination of the lysosomal membrane to engulf cytoplasmic material and is less well-characterized in mammalian cells. **Chaperone-mediated autophagy (CMA)** selectively degrades proteins containing a KFERQ-like motif. The cytoplasmic chaperone Hsc70 recognizes this motif and delivers the protein to the LAMP-2A receptor on the lysosomal surface, through which the unfolded protein translocates into the lysosomal lumen for degradation.
### V. Molecular Mechanism of Macroautophagy
The initiation and regulation of macroautophagy is tightly controlled by nutrient-sensing kinases. **mTORC1** is the master negative regulator: under nutrient-rich conditions, active mTORC1 phosphorylates and inhibits the ULK1 complex, suppressing autophagy. During starvation, mTORC1 becomes inactive, releasing ULK1 to initiate autophagosome formation. **AMPK**, an energy sensor activated by a high AMP-to-ATP ratio, promotes autophagy both by inhibiting mTORC1 and by directly activating ULK1. The **ULK1 complex** (comprising ULK1, ATG13, FIP200, and ATG101) initiates the process.
During **nucleation**, ULK1 activates the **Beclin 1/VPS34 complex** (a Class III PI3 kinase), which generates PI3P on the isolation membrane (phagophore). PI3P recruits effector proteins including WIPI2 that promote membrane expansion. **Elongation** of the phagophore depends on two ubiquitin-like conjugation systems. The **ATG12-ATG5-ATG16L1 complex**, assembled by ATG7 (E1-like) and ATG10 (E2-like) enzymes, acts as an E3-like enzyme for the second system. In this second system, **LC3** (ATG8) is processed by ATG4 protease to LC3-I, which is then conjugated to phosphatidylethanolamine (PE) by ATG7 and ATG3 to form LC3-II. LC3-II is inserted into the autophagosome membrane and is the most widely used marker for monitoring autophagy.
**Selective autophagy** employs dedicated **autophagy receptors** such as p62/SQSTM1, NBR1, OPTN, and NDP52 that simultaneously bind ubiquitinated cargo and LC3 on the autophagosome, linking specific targets to the degradation machinery. **Mitophagy**, the selective removal of damaged mitochondria, is mediated by the PINK1/Parkin pathway: when a mitochondrion loses its membrane potential, PINK1 accumulates on the outer membrane and recruits the E3 ligase Parkin from the cytoplasm. Parkin ubiquitinates outer membrane proteins, and autophagy receptors bridge the ubiquitinated mitochondrion to LC3 on the forming autophagosome.
The completed autophagosome fuses with a lysosome (requiring Rab7, SNAREs, and the HOPS tethering complex). The inner membrane and all enclosed cargo are degraded by lysosomal hydrolases, and the resulting amino acids, lipids, and nucleotides are exported back to the cytoplasm for reuse.
The macroautophagy pathway. Panel A: Regulation — mTORC1 (active in nutrient-rich conditions) inhibits ULK1 complex; starvation or AMPK activation relieves this inhibition. Panel B: Sequential steps — (1) Initiation: ULK1 complex activates Beclin 1/VPS34 to generate PI3P on the phagophore membrane. (2) Elongation: ATG12-ATG5-ATG16L1 complex and LC3-II (lipidated with PE) promote membrane expansion, forming a double-membrane autophagosome around cytoplasmic cargo (damaged mitochondrion and protein aggregates shown). (3) Selective cargo recognition: p62 receptors bridge ubiquitinated cargo to LC3 on the autophagosome. (4) Closure and fusion with lysosome to form autolysosome. (5) Degradation and nutrient recycling. Each step labeled with key ATG proteins involved.
### VI. Physiological and Pathological Roles of Autophagy
Autophagy serves numerous essential physiological functions. It provides nutrient recycling during starvation by generating amino acids from bulk protein degradation. It performs quality control by removing damaged organelles (mitophagy) and protein aggregates (aggrephagy). During development, it clears maternal proteins during embryogenesis. In immunity, xenophagy destroys intracellular pathogens such as Mycobacterium and Salmonella, and autophagy delivers antigens to MHC class II molecules for presentation. During erythrocyte maturation, autophagy removes mitochondria and other organelles.
In disease, autophagy plays complex and sometimes paradoxical roles. In **neurodegeneration**, impaired autophagy leads to accumulation of toxic protein aggregates implicated in Alzheimer's (amyloid-beta, tau), Parkinson's (alpha-synuclein), and Huntington's (polyglutamine huntingtin) diseases. PINK1 and Parkin mutations that cause defective mitophagy lead to autosomal recessive Parkinson's disease. In **cancer**, autophagy has a dual role: it acts as a tumor suppressor (Beclin 1 is a haploinsufficient tumor suppressor, and autophagy limits ROS by removing damaged organelles), but established tumors exploit autophagy to survive nutrient and oxygen stress. Some pathogens evade or exploit autophagy for their own benefit. Autophagy declines with aging, and enhancing autophagy extends lifespan in model organisms.
Lysosomes have also emerged as important **signaling platforms**. mTORC1 is activated on the lysosomal surface through the Ragulator complex and Rag GTPases. The transcription factor **TFEB** is a master regulator of lysosomal biogenesis: when mTORC1 is active, it phosphorylates TFEB and retains it in the cytoplasm. During starvation, mTORC1 inactivation allows TFEB to be dephosphorylated and translocate to the nucleus, where it activates genes encoding lysosomal enzymes, autophagy proteins, and lysosomal membrane proteins.
---